By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cell Signaling Technology today announced it has licensed its patent rights and proprietary antibody reagents related to the detection of epidermal growth factor receptor mutations to Ventana Medical Systems.

The non-exclusive licensing agreement is for the field of tissue-based in vitro diagnostics testing, the Danvers, Mass.-based antibody firm said. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.